- Home
- VINP vs CMPX Comparison
VINP vs CMPX Comparison
Compare VINP & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- CMPX
- Stock Information
- Founded
- VINP 2009
- CMPX 2014
- Country
- VINP Brazil
- CMPX United States
- Employees
- VINP N/A
- CMPX N/A
- Industry
- VINP Investment Managers
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- CMPX Health Care
- Exchange
- VINP Nasdaq
- CMPX Nasdaq
- Market Cap
- VINP 714.7M
- CMPX 730.9M
- IPO Year
- VINP 2021
- CMPX N/A
- Fundamental
- Price
- VINP $11.93
- CMPX $4.20
- Analyst Decision
- VINP Strong Buy
- CMPX Strong Buy
- Analyst Count
- VINP 3
- CMPX 7
- Target Price
- VINP $13.33
- CMPX $14.43
- AVG Volume (30 Days)
- VINP 67.6K
- CMPX 1.8M
- Earning Date
- VINP 11-13-2025
- CMPX 11-05-2025
- Dividend Yield
- VINP 5.44%
- CMPX N/A
- EPS Growth
- VINP N/A
- CMPX N/A
- EPS
- VINP 0.50
- CMPX N/A
- Revenue
- VINP $153,475,995.00
- CMPX N/A
- Revenue This Year
- VINP $67.78
- CMPX N/A
- Revenue Next Year
- VINP $14.48
- CMPX N/A
- P/E Ratio
- VINP $23.78
- CMPX N/A
- Revenue Growth
- VINP 76.11
- CMPX N/A
- 52 Week Low
- VINP $8.66
- CMPX $1.27
- 52 Week High
- VINP $11.99
- CMPX $4.86
- Technical
- Relative Strength Index (RSI)
- VINP 72.47
- CMPX 58.66
- Support Level
- VINP $11.38
- CMPX $3.50
- Resistance Level
- VINP $11.66
- CMPX $3.95
- Average True Range (ATR)
- VINP 0.21
- CMPX 0.27
- MACD
- VINP 0.03
- CMPX -0.02
- Stochastic Oscillator
- VINP 89.13
- CMPX 90.85
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.